LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

LLY

866.44

+0.98%↑

UNH

557.63

-1.37%↓

NVO

133.1

+1.18%↑

JNJ

154.19

-0.25%↓

MRK

125.63

-0.1%↓

Search

Bluebird Bio Inc

Fermé

1.12 7.69

Résumé

Variation du prix de l'action

24h

Actuel

Min

1.04

Max

1.13

Chiffres clés

By Trading Economics

Revenu

-72M

Ventes

12M

BPA

-0.66

Marge bénéficiaire

-578.849

EBITDA

-84M

Recommandations

By TipRanks

Recommandations

Achat

Prévisions sur 12 Mois

+376.19 upside

Dividendes

By Dow Jones

Prochains Résultats

6 août 2024

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

5.7M

240M

Ouverture précédente

-6.57

Clôture précédente

1.12

Score Technique

By Trading Central

Confiance

Strong Bearish Evidence

Bluebird Bio Inc Graphique

Actualités Associées

8 déc. 2023, 20:56 UTC

Principaux Mouvements du Marché

Bluebird Bio Shares Slide 41% on Black-Box Label, Higher Price for Sickle-Cell Treatment

8 déc. 2023, 18:45 UTC

Actualités

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- 2nd Update

8 déc. 2023, 16:45 UTC

Actualités

FDA Approves World's First Crispr Gene-Editing Drug for Sickle-Cell Disease -- Update

24 nov. 2023, 12:00 UTC

Actualités

Gene Editing Will Change Medicine -- and Maybe Health Investing Too -- Heard on the Street -- WSJ

Comparaison

Variation de prix

Bluebird Bio Inc prévision

Objectif de Prix

By TipRanks

376.19% hausse

Prévisions sur 12 Mois

Moyen 5 USD  376.19%

Haut 8 USD

Bas 1 USD

Basé sur 7 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat

7 ratings

3

Achat

3

Maintien

1

Vente

Score Technique

By Trading Central

1 / 1.13Support & Résistance

Court Terme

Strong Bearish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

No Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

EBITDA

Bénéfice d'exploitation

$

À Propos Bluebird Bio Inc

bluebird bio, Inc. is a biotechnology company. The Company focusing on researching, developing and commercializing potentially transformative gene therapies for severe genetic diseases and cancer. It develops LentiGlobin for sickle cell disease (SCD) as a one-time treatment for patients with SCD, a hereditary blood disorder resulting from a mutation in the ß-globin gene that causes polymerization of hemoglobin proteins, resulting in abnormal red blood cell function. It builds an integrated product platform with therapeutic in a variety of indications based on its lentiviral gene addition platform, gene editing and cancer immunotherapy capabilities. Its programs in genetic disease include betibeglogene autotemcel; LentiGlobin gene therapy for sickle cell disease (SCD); and elivaldogene autotemcel. Its programs in oncology are focused on developing novel T cell-based immunotherapies, including chimeric antigen receptor (CAR) and T cell receptor (TCR) T cell therapies.